Sign inCreate account

Report workspace tools

NCT07055607ENROLLING_BY_INVITATIONanonymous

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Sponsor

Source record

Novo Nordisk A/S

Phase

Source record

registry-stage

Modality

AI-normalized

small molecule

Target

AI-normalized

Semaglutide

Indication / condition

AI-normalized

Obesity

Intervention

Source record

Semaglutide

Source & freshness

Source record

NCT ID

NCT07055607

Original source

ClinicalTrials.gov

Source last updated

May 14, 2026

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07055607

Title

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Sponsor

Novo Nordisk A/S

Status

ENROLLING_BY_INVITATION

Phase

registry-stage

Condition raw

Obesity

Condition normalized

Obesity

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Semaglutide

Target normalized

Semaglutide

Interventions

Semaglutide

Public preview

Source record

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity. SEO and diligence focus: Semaglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07055607

Status

ENROLLING_BY_INVITATION

Phase

registry-stage

Sponsor

Novo Nordisk A/S

Executive brief

Investment-Ready Snapshot

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity. SEO and diligence focus: Semaglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 14, 2026
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07055607

Indication

Obesity

Modality

small molecule

Target

Semaglutide

Intervention

Semaglutide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.